Six host-range restricted poxviruses from three genera induce distinct gene expression profiles in an in vivo mouse model

BMC Genomics

Volumn 16, Issue 1, 2015, Pages

  Offerman, Kristy ^a   Deffur, Armin ^a   Carulei, Olivia ^a   Wilkinson, Robert ^a,b,c   Douglass, Nicola ^a   Williamson, Anna Lise ^a,d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Avipoxviruses; LSDV; Micro array; MVA; Poxvirus; Vaccine

Indexed keywords

IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN M; INTERFERON; VIRUS VECTOR; IMMUNOGLOBULIN G; TRANSCRIPTOME; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AVIPOXVIRUS; BAGG ALBINO MOUSE; CANARYPOX VIRUS; CAPRIPOXVIRUS; CONTROLLED STUDY; FEMALE; FERAL PIGEONPOX VIRUS; FOWLPOX VIRUS; GENE EXPRESSION PROFILING; HOST RANGE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IGHG GENE; IGHG3 GENE; IGHM GENE; IMMUNE RESPONSE; IMMUNOGLOBULIN GENE; IN VIVO STUDY; INFECTION RISK; LUMPY SKIN DISEASE VIRUS; MODIFIED VACCINIA ANKARA VIRUS; MOUSE; NONHUMAN; PENGUINPOX VIRUS; POPULATION ABUNDANCE; POXVIRIDAE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SPECIES COMPARISON; SPECIES DIFFERENCE; SPLEEN; UPREGULATION; ANIMAL; GENE VECTOR; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENICITY;

AVIPOXVIRUS; CANARYPOX VIRUS; FOWLPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LUMPY SKIN DISEASE VIRUS; MUS; PIGEONPOX VIRUS; POXVIRIDAE;

ANIMALS; FEMALE; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HOST SPECIFICITY; HUMANS; IMMUNOGLOBULIN G; INTERFERONS; MICE; MICE, INBRED BALB C; POXVIRIDAE; TRANSCRIPTOME; UP-REGULATION; VACCINES;

EID: 84936091620     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-015-1659-1     Document Type: Article

References (73)

1. Garcia-Arriaza J, Esteban M. Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother. 2014;10(8):2235-44.
2. Gomez CE, Perdiguero B, Garcia-Arriaza J, Esteban M. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother. 2012;8(9):1192-207.
3. Burgers WA, Ginbot Z, Shen YJ, Chege GK, Soares AP, Muller TL, et al. The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques. J Gen Virol. 2014;95(Pt 10):2267-72.
4. Draper SJ, Cottingham MG, Gilbert SC. Utilizing poxviral vectored vaccines for antibody induction-progress and prospects. Vaccine. 2013;31(39):4223-30.
5. Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther. 2012;12(4):463-78.
6. Aspden K, Passmore JA, Tiedt F, Williamson AL. Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector. J Gen Virol. 2003;84(Pt 8):1985-96.
7. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-20.
8. Baxby D, Paoletti E. Potential use of non-replicating vectors as recombinant vaccines. Vaccine. 1992;10(1):8-9.
9. Moss B. Vaccinia and other poxvirus expression vectors. Curr Opin Biotechnol. 1992;3(5):518-22.
10. Guerra S, Gonzalez JM, Climent N, Reyburn H, Lopez-Fernandez LA, Najera JL, et al. Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J Virol. 2010;84(16):8141-52.
11. Guerra S, Lopez-Fernandez LA, Conde R, Pascual-Montano A, Harshman K, Esteban M. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol. 2004;78(11):5820-34.
12. Guerra S, Lopez-Fernandez LA, Pascual-Montano A, Munoz M, Harshman K, Esteban M. Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J Virol. 2003;77(11):6493-506.
13. Guerra S, Lopez-Fernandez LA, Pascual-Montano A, Najera JL, Zaballos A, Esteban M. Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells. J Virol. 2006;80(2):985-98.
14. Guerra S, Najera JL, Gonzalez JM, Lopez-Fernandez LA, Climent N, Gatell JM, et al. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol. 2007;81(16):8707-21.
15. Harenberg A, Guillaume F, Ryan EJ, Burdin N, Spada F. Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells. Vaccine. 2008;26(39):5004-13.
16. Teigler JE, Phogat S, Franchini G, Hirsch VM, Michael NL, Barouch DH. The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol. 2014;88(3):1809-14.
17. Pacchioni S, Volonte L, Zanotto C, Pozzi E, De Giuli MC, Radaelli A. Canarypox and fowlpox viruses as recombinant vaccine vectors: an ultrastructural comparative analysis. Arch Virol. 2010;155(6):915-24.
18. Zanotto C, Pozzi E, Pacchioni S, Volonte L, De Giuli MC, Radaelli A. Canarypox and fowlpox viruses as recombinant vaccine vectors: a biological and immunological comparison. Antivir Res. 2010;88(1):53-63.
19. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev. 2009;227(1):75-86.
20. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol. 2009;10(1):116-25.
21. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. 2011;12(8):786-95.
22. Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci U S A. 2012;109(50):E3503-12.
23. Lousberg EL, Diener KR, Brown MP, Hayball JD. Innate immune recognition of poxviral vaccine vectors. Expert Rev Vaccines. 2011;10(10):1435-49.
24. Johnson MJ, Petrovas C, Yamamoto T, Lindsay RW, Lore K, Gall JG, et al. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J Immunol. 2012;188(12):6109-18.
25. Najera JL, Gomez CE, Domingo-Gil E, Gherardi MM, Esteban M. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol. 2006;80(12):6033-47.
26. Offerman K, Carulei O, Gous TA, Douglass N, Williamson AL. Phylogenetic and histological variation in avipoxviruses isolated in South Africa. J Gen Virol. 2013;94(Pt 10):2338-51.
27. Offerman K, Carulei O, van der Walt AP, Douglass N, Williamson AL. The complete genome sequences of poxviruses isolated from a penguin and a pigeon in South Africa and comparison to other sequenced avipoxviruses. BMC Genomics. 2014;15:463.
28. Stannard LM, Marais D, Kow D, Dumbell KR. Evidence for incomplete replication of a penguin poxvirus in cells of mammalian origin. J Gen Virol. 1998;79(Pt 7):1637-46.
29. Carulei O, Douglass N, Williamson AL. Phylogenetic analysis of three genes of Penguinpox virus corresponding to Vaccinia virus G8R (VLTF-1), A3L (P4b) and H3L reveals that it is most closely related to Turkeypox virus, Ostrichpox virus and Pigeonpox virus. Virol J. 2009;6:52.
30. Rubins KH, Hensley LE, Relman DA, Brown PO. Stunned silence: gene expression programs in human cells infected with monkeypox or vaccinia virus. PLoS One. 2011;6(1):e15615.
31. Brum LM, Lopez MC, Varela JC, Baker HV, Moyer RW. Microarray analysis of A549 cells infected with rabbitpox virus (RPV): a comparison of wild-type RPV and RPV deleted for the host range gene, SPI-1. Virology. 2003;315(2):322-34.
32. Matsumiya T, Stafforini DM. Function and regulation of retinoic acid-inducible gene-I. Crit Rev Immunol. 2010;30(6):489-513.
33. Ruffell D, Mourkioti F, Gambardella A, Kirstetter P, Lopez RG, Rosenthal N, et al. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc Natl Acad Sci U S A. 2009;106(41):17475-80.
34. Poli V. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem. 1998;273(45):29279-82.
35. Abele R, Tampe R. Function of the transport complex TAP in cellular immune recognition. Biochim Biophys Acta. 1999;1461(2):405-19.
36. Petit V, Guetard D, Renard M, Keriel A, Sitbon M, Wain-Hobson S, et al. Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo. J Mol Biol. 2009;385(1):65-78.
37. Ghosh S, Gregory D, Smith A, Kobzik L. MARCO regulates early inflammatory responses against influenza: a useful macrophage function with adverse outcome. Am J Respir Cell Mol Biol. 2011;45(5):1036-44.
38. Coelho AL, Schaller MA, Benjamim CF, Orlofsky AZ, Hogaboam CM, Kunkel SL. The chemokine CCL6 promotes innate immunity via immune cell activation and recruitment. J Immunol. 2007;179(8):5474-82.
39. Kim YG, Park JH, Reimer T, Baker DP, Kawai T, Kumar H, et al. Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe. 2011;9(6):496-507.
40. Chen SC, Vassileva G, Kinsley D, Holzmann S, Manfra D, Wiekowski MT, et al. Ectopic expression of the murine chemokines CCL21a and CCL21b induces the formation of lymph node-like structures in pancreas, but not skin, of transgenic mice. J Immunol. 2002;168(3):1001-8.
41. Shimizu Y, Honda S, Yotsumoto K, Tahara-Hanaoka S, Eyre HJ, Sutherland GR, et al. Fc(alpha)/mu receptor is a single gene-family member closely related to polymeric immunoglobulin receptor encoded on Chromosome 1. Immunogenetics. 2001;53(8):709-11.
42. Baalasubramanian S, Harris CL, Donev RM, Mizuno M, Omidvar N, Song WC, et al. CD59a is the primary regulator of membrane attack complex assembly in the mouse. J Immunol. 2004;173(6):3684-92.
43. Sempowski GD, Lee DM, Kaufman RE, Haynes BF. Structure and function of the CD7 molecule. Crit Rev Immunol. 1999;19(4):331-48.
44. Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 2013;41(Database issue):D1040-6.
45. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A. 1998;95(26):15623-8.
46. Schlaak JF, Hilkens CM, Costa-Pereira AP, Strobl B, Aberger F, Frischauf AM, et al. Cell-type and donor-specific transcriptional responses to interferon-alpha. Use of customized gene arrays. J Biol Chem. 2002;277(51):49428-37.
47. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med. 2006;203(2):413-24.
48. Pulendran B. Variegation of the immune response with dendritic cells and pathogen recognition receptors. J Immunol. 2005;174(5):2457-65.
49. Somogyi P, Frazier J, Skinner MA. Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology. 1993;197(1):439-44.
50. Offerman K. Investigation of local South African avipoxviruses as potential vaccine vectors. Cape Town: University of Cape Town; 2014.
51. Taylor J, Meignier B, Tartaglia J, Languet B, VanderHoeven J, Franchini G, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 1995;13(6):539-49.
52. Tulman ER, Afonso CL, Lu Z, Zsak L, Kutish GF, Rock DL. The genome of canarypox virus. J Virol. 2004;78(1):353-66.
53. Bourquain D, Dabrowski PW, Nitsche A. Comparison of host cell gene expression in cowpox, monkeypox or vaccinia virus-infected cells reveals virus-specific regulation of immune response genes. Virol J. 2013;10:61.
54. Bahar MW, Kenyon JC, Putz MM, Abrescia NG, Pease JE, Wise EL, et al. Structure and function of A41, a vaccinia virus chemokine binding protein. PLoS Pathog. 2008;4(1):e5.
55. Clark RH, Kenyon JC, Bartlett NW, Tscharke DC, Smith GL. Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol. 2006;87(Pt 1):29-38.
56. Shen YJ, Shephard E, Douglass N, Johnston N, Adams C, Williamson C, et al. A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV). Virol J. 2011;8:265.
57. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect/Institut Pasteur. 2002;4(4):449-60.
58. Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol. 2008;20(1):17-22.
59. Luscher B. Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene. 2001;277(1-2):1-14.
60. Wang X, Han Y, Dang Y, Fu W, Zhou T, Ptak RG, et al. Moloney leukemia virus 10 (MOV10) protein inhibits retrovirus replication. J Biol Chem. 2010;285(19):14346-55.
61. Yates NL, Liao HX, Fong Y, de Camp A, Vandergrift NA, Williams WT, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014;6(228):228ra239.
62. Liu SY, Sanchez DJ, Cheng G. New developments in the induction and antiviral effectors of type I interferon. Curr Opin Immunol. 2011;23(1):57-64.
63. Miettinen M, Sareneva T, Julkunen I, Matikainen S. IFNs activate toll-like receptor gene expression in viral infections. Genes Immun. 2001;2(6):349-55.
64. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7(2):99-109.
65. Sollberger G, Strittmatter GE, Kistowska M, French LE, Beer HD. Caspase-4 is required for activation of inflammasomes. J Immunol. 2012;188(4):1992-2000.
66. Dalman MR, Deeter A, Nimishakavi G, Duan ZH. Fold change and p-value cutoffs significantly alter microarray interpretations. BMC Bioinformatics. 2012;13 Suppl 2:S11.
67. Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2012. 2013. Available from: http://www.R-project.org ISBN 3-900051-07-0.
68. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-64.
69. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307-15.
70. Gentleman R, Carey V, Huber W, Hahne F. Genefilter: Methods for filtering genes from microarray experiments. R package version 2011, 1(0). http://www.bioconductor.org/packages/release/bioc/html/genefilter.html .
71. Smyth GK. Limma: linear models for microarray data. In: Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer; 2005. p. 397-420.
72. Warnes GR, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, Lumley T, Maechler M, Magnusson A, Moeller S. gplots: Various R programming tools for plotting data. R package version 2009, 2(4). http://cran.r-project.org/web/packages/gplots/gplots.pdf .
73. Oliveros JC. VENNY. An interactive tool for comparing lists with Venn Diagrams. 2007.